20 completed, 4 terminated, 3 recruiting, 1 active not recruiting. 30 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 30 | Completed 20, Terminated 4, Recruiting 3, Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 5 | Terminated 3, Completed 1, Withdrawn 1 |
Follow Foot Diseases: new trials by email Literature Review of Foot Diseases trials Research Report on Foot Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b Study of ZYG24004 in Participants With Tinea Pedis Caused by Dermatophytes ZYG24004 1% topical film-forming formulation, ZYG24004 3% topical film-forming formulation, Placebo topical formulation - Tinea Pedis | Phase 1 | Recruiting | Sinomune Pharmaceutical Co., Ltd | 64 | 2026-07-21 | 2026-08-04 |
| Lateral Plantar Artery Embolization For Plantar Fasciitis Lipiodol - Plantar Fasciitis, Chronic, Plantar Fasciitis | Phase 1 | Recruiting | Joint & Vascular Institute | 10 | 2025-12-20 | 2026-02-09 |
| Resiniferatoxin for the Management of Refractory Morton s Neuroma Pain Resiniferatoxin - Morton's Neuroma | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 3 | 2025-03-13 | 2026-04-13 |
| Clinical Effects of Incobotulinum Toxin vs Corticosteroid in Plantar Fascitis Incobotulinum Toxin A, Glucocorticoid - Plantar Fasciitis of Both Feet, Pain | Phase 1 | Active not recruiting | Instituto Mexicano del Seguro Social | 20 | 2024-09-01 | 2025-01-23 |
| Infracalcaneal Peppering Injection Technique for Chronic Plantar Fasciitis Corticosteroid injection (CSI) with local anesthetic (LA), Local anesthetic (LA) with Saline injection - Chronic Plantar Fasciitis | Phase 1 | Completed | Wake Forest University Health Sciences | 41 | 2023-10-18 | 2025-10-30 |
| Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis UHE-103 Cream, Naftin (naftifine hydrochloride) Cream - Tinea Cruris, Tinea Pedis | Phase 1 | Completed | Therapeutics, Inc. | 42 | 2022-02-17 | 2024-04-10 |
| Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers Control; Standard-of-care management, Only PRP injection, PRP + SVF injection - Diabetic Foot Ulcer, Diabetes Mellitus | Phase 1 | Recruiting | University of the Punjab | 28 | 2020-11-20 | 2024-12-31 |
| Iontophoresis of Treprostinil to Enhance Wound Healing in Diabetic Foot Skin Ulcers Treprostinil iontophoresis, Remodulin® placebo iontophoresis - Diabetic Foot Ulcer | Phase 1 / Phase 2 | Terminated | University Hospital, Grenoble | 4 | 2020-01-28 | 2023-12-12 |
| Treatment of Chronic Wounds in Diabetic Foot Syndrome With Allogeneic Adipose Derived Mesenchymal Stem Cells Application of allogeneic ADSC stem cells in fibrin gel, Standard care in diabetic foot ulcer - Diabetic Foot Ulcer | Phase 1 / Phase 2 | Completed | Medical University of Warsaw | 46 | 2019-07-01 | 2021-10-14 |
| Compare Ultrasound Assisted Cold Therapy and Lidocaine Injection to Treat Morton's Neuroma Cryoablation, Lidocaine, Saline - Intermetatarsal Neuroma | Phase 1 | Completed | Icahn School of Medicine at Mount Sinai | 10 | 2016-07-01 | 2018-11-06 |
| Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients Selinexor, Standard-of-Care, Vehicle Gel - Diabetic Foot Ulcers | Phase 1 / Phase 2 | Withdrawn | Karyopharm Therapeutics Inc | 2015-01-01 | 2023-01-20 | |
| EZCast-DFU Study With Portal for Application of Topical Medications Collagenase ointment, Modified Contact Cast System - Foot Ulcer, Diabetic Foot | Phase 1 | Completed | University of Miami | 4 | 2014-10-01 | 2015-06-10 |
| Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis Naftifine Hydrochloride Gel 2%, Naftin® Gel 2%, Placebo Topical Gel - Tinea Pedis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1519 | 2014-06-27 | 2018-09-06 |
| Study to Evaluate the Safety and Tolerability of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma) CTNX-4975 - Morton's Neuroma | Phase 1 | Completed | Centrexion Therapeutics | 11 | 2014-02-01 | 2015-09-15 |
| Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers Gentamicin Topical Gel, Ciprofloxacin, Doxycycline - Diabetic Foot Ulcers | Phase 1 / Phase 2 | Terminated | Royer Biomedical, Inc. | 9 | 2014-01-01 | 2015-05-14 |
| Effect of Local Application of Boron on Diabetic Foot Ulcers boron gel, Placebo - Diabetic Foot Ulcer | Phase 1 | Unknown | Bezmialem Vakif University | 100 | 2014-01-01 | 2014-11-25 |
| Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis Naftifine Hydrochloride Cream 2%, Naftin® (Naftifine Hydrochloride) Cream 2%, Placebo Topical Cream - Tinea Pedis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 890 | 2013-08-01 | 2017-05-09 |
| Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis Naftifine HCl Cream 1%, Naftin® (Naftifine HCl) Cream 1%, Placebo topical cream - Tinea Pedis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1053 | 2012-05-01 | 2014-05-06 |
| Hygienic Socks With Antifungal Agent-loaded Microcapsules for Patients With Tinea Pedis Anti-fungal agent (Clotrimazole) loaded microcapsules, Placebo - Tinea Pedis | Phase 1 | Completed | Prof. Yuen Chun-Wah | 42 | 2012-01-01 | 2013-04-02 |
| Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis Butenafine Hydrochloride Cream, 1%, Lotrimin Ultra®, Butenafine Vehicle - Tinea Pedis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 707 | 2012-01-01 | 2017-05-05 |
Showing 20 of 30. Sign in to see all of them.
Tinea Pedis (13) · Foot Ulcer (11) · Diabetic Foot (9) · Diabetes Mellitus (8) · Fasciitis, Plantar (3) · Morton Neuroma (3) · Peripheral Nervous System Diseases (2) · Diabetes Complications (1) · Foot Deformities (1) · Foot Injuries (1) · Infections (1) · Motor Activity (1) · Onycholysis (1) · Onychomycosis (1) · Pain (1)
Skin Diseases (24) · Skin and Connective Tissue Diseases (24) · Pathological Conditions, Signs and Symptoms (17) · Signs and Symptoms (17) · Bacterial Infections and Mycoses (13) · Dermatomycoses (13) · Foot Dermatoses (13) · Infections (13) · Mycoses (13) · Pruritus (13) · Skin Diseases, Infectious (13) · Skin Manifestations (13) · Tinea (13) · Endocrine System Diseases (11)
naftifine (4) · butenafine (3) · Standard of Care (2) · Adrenal Cortex Hormones (1) · Anesthetics, Local (1) · Borates (1) · Capsaicin (1) · Ciprofloxacin (1) · Clotrimazole (1) · Collagenases (1) · Craniospinal Irradiation (1) · Cryosurgery (1) · Doxycycline (1) · Drug Evaluation (1) · Glucocorticoids (1)
Sun Pharmaceutical Industries, Inc. (7) · Bezmialem Vakif University (1) · Centrexion Therapeutics (1) · CoMentis (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Genentech, Inc. (1) · Icahn School of Medicine at Mount Sinai (1) · Instituto Mexicano del Seguro Social (1) · Joint & Vascular Institute (1) · Karyopharm Therapeutics Inc (1) · Medical University of Warsaw (1) · National Institutes of Health Clinical Center (CC) (1) · NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) (1) · Pfizer (1) · Prof. Yuen Chun-Wah (1)
United States (14) · Australia (1) · Belize (1) · China (1) · France (1) · Hong Kong (1) · Mexico (1) · New Zealand (1) · Pakistan (1) · Poland (1) · Turkey (Türkiye) (1)
Andrew J Mannes, M.D. (1) · Azra Mehmood, PhD (1) · Beata Mrozikiewicz-Rakowska, . Assoc.Prof. (1) · Chun Wah M. Yuen (1) · Cracowski Jean-luc, Professor (1) · David Gratton, MD (1) · David Spinner, DO (1) · Debra Breneman, MD (1) · Eduardo Tschen, MD (1) · Henry Hsu, MD (1) · Joseph Fowler, MD (1) · Joseph W LeMaster, MD, MPH (1) · Lynda Spelman, MD (1) · Michael A Jones, DPM (1)
2016 (1), R01HD036802 (1), UL1TR001420 (1)